Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Measuring Acute Drug Demand in Humans II
NCT07043452Phase 1Withdrawn
- Sponsor
- Johns Hopkins University
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cannabinoid ophthalmic solution and morphine (6 arms), sponsored by Johns Hopkins University. Primary endpoints: Demand Intensity - Consumption of Blinded Drug at Unconstrained Price, Breakpoint - Maximum Price Paid for Blinded Drug and 2 more. Planned start Nov 2025; status: withdrawn.
02
Drugs
cannabinoid ophthalmic solutionmorphine
Beyond the preview
Go deeper on NCT07043452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07043452.